On World AIDS Day, Mylan Announces Plans to be the First to Market Newly-Recommended Antiretroviral Treatment for $99 Per Patient, Per Year "TLE400," upon regulatory approval by the U.S. FDA, will contain Tenofovir Disoproxyl Fumarate, Lamivudine and a reduced dose of EfavirenzNewly updated World Health Organization guidelines recommend TLE400 as an alternative first-line regimen for people on AIDS treatment in developing countries

HERTFORDSHIRE, England, BANGALORE, India and PITTSBURGH, Dec. 1, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it expects to be the first to launch, upon regulatory approval and for developing country markets funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 mg + Lamivudine 300 mg + Efavirenz 400 mg) for $99 per patient, per year. Mylan partnered with the Clinton Health Access Initiative (CHAI) to develop TLE400. The significantly reduced price could generate savings of tens of millions of dollars for national AIDS programs that aim to double the 15 million people on antiretroviral (ARV) treatment in developing countries. Mylan...